ALZHEIMER'S DISEASE THERAPEUTIC APPROACHES
DOI:
https://doi.org/10.22159/ajpcr.2018.v11i7.25104Keywords:
Proteins, Misfolding, Nil, Type 2 diabetes mellitus, Neurofibrillary tangles, Amyloidosis, NilAbstract
A protein is a large biomolecule which consists of one or more chains of amino acid residues. Proteins exhibit a biological phenomenon in which, they are misfolded as aggregates (i.e., accumulate and clump together) either intra- or extracellularly. This process plays a central role in the pathogenesis of Alzheimer's disease (AD) and diabetes mellitus (DM) - 2 and common for many degenerative diseases. In this case, the histopathological consequences of protein misfolding such as sensile plaques and neurofibrillary tangles in AD and lewy bodies in Parkinson's disease occur. 8–10% of adult population shares risk factors with AD. Amyloid fibrils which build up in tissue as an abnormal protein form Amyloidosis. Conformational change in three-dimensional structure forms amyloid fibrils. Type 2 DM is characterized by the deposition of islet amyloid polypeptide within beta cells of the pancreas which leads to chronic cerebral hypoperfusion that result in degeneration of neuroglial cells.
Downloads
References
Ross CA, Poirier MA. Protein aggregation and neurodegenerative disease. Nat Med 2004;10 Suppl: S10-7.
Nussbaum RL, Ellis CE. Alzheimer’s disease and Parkinson’s disease. N Engl J Med 2003;348:1356-64.
Askanas V, Engel WK. Unfolding story of inclusion body myositis and myopathies: Role of misfolded proteins, amyloid-,6, cholesterol, and aging. J Child Neurol 2003;18:185.
Cummings BJ, Su JH, Geddes JW, Van Nostrand WE, Wagner SL, Cunningham DD, et al. Aggregation of the amyloid precursor protein within degenerating neurons and dystrophic neurites in Alzheimer’s disease. Neuroscience 1992;48:763-77.
Ballew RM, Sabelko J, Gruebele M. Direct observation of fast protein folding: The initial collapse of apomyoglobin. Proc Natl Acad Sci U S A 1996;93:5759-64.
Ross CA, Pickart CM. The ubiquitin-proteasome pathway in Parkinson’s disease and other neurodegenerative diseases. Trends Cell Biol 2004;14:703-11.
Forloni G, Iussich S, Awan T, Colombo L, Angeretti N, Girola L, et al. Tetracyclines affect prion infectivity. Proc Natl Acad Sci U S A 2002;99:10849-54.
Dobson CM. Protein chemistry. In the footsteps of alchemists. Science 2004;304:1259-62.
Kelly JW. Structural biology: Proteins downhill all the way. Nature 2006;442:255-6.
Wong PC, Cai H, Borchelt DR, Price DL. Genetically engineered mouse models of neurodegenerative diseases. Nat Neurosci 2002;5:633-9.
Ballatore C, Lee VM, Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer’s disease and related disorders. Nat Rev Neurosci 2007;8:663-72.
Fink AL. Protein aggregation: Folding aggregates, inclusion bodies and amyloid. Fold Des 1998;3:R9-23.
Soto C. Unfolding the role of protein misfolding in neurodegenerative diseases. Nat Rev Neurosci 2003;4:49-60.
Wu C, Shea JE. Structural similarities and differences between amyloidogenic and non-amyloidogenic islet amyloid polypeptide (IAPP) sequences and implications for the dual physiological and pathological activities of these peptides. PLoS Comput Biol 2013;9:e1003211.
Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, et al. Global prevalence of dementia: A Delphi consensus study. Lancet 2005;366:2112-7.
Bentahir M, Nyabi O, Verhamme J, Tolia A, Horré K, Wiltfang J, et al. Presenilin clinical mutations can affect gamma-secretase activity by different mechanisms. J Neurochem 2006;96:732-42.
Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y, et al. Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: Evidence that an initially deposited species is A beta 42(43). Neuron 1994;13:45-53.
Mathis CA, Klunk WE, Price JC, DeKosky ST. Imaging technology for neurodegenerative diseases: Progress toward detection of specific pathologies. Arch Neurol 2005;62:196-200.
Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K, et al. Amyloid plaque core protein in Alzheimer disease and down syndrome. Proc Natl Acad Sci U S A 1985;82:4245-9.
Lemere CA, Blusztajn JK, Yamaguchi H, Wisniewski T, Saido TC, Selkoe DJ, et al. Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in down syndrome: Implications for initial events in amyloid plaque formation. Neurobiol Dis 1996;3:16-32.
de Leon MJ, DeSanti S, Zinkowski R, Mehta PD, Pratico D, Segal S, et al. MRI and CSF studies in the early diagnosis of Alzheimer’s disease. J Intern Med 2004;256:205-23.
Masdeu JC, Zubieta JL, Arbizu J. Neuroimaging as a marker of the onset and progression of Alzheimer’s disease. J Neurol Sci 2005;236:55-64.
McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr. Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the national institute on aging- Alzheimer’s association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011;7:263-9.
Orrego F, Villanueva S. The chemical nature of the main central excitatory transmitter: A critical appraisal based upon release studies and synaptic vesicle localization. Neuroscience 1993;56:539-55.
Doody RS, Stevens JC, Beck C, Dubinsky RM, Kaye JA, Gwyther L, et al. Practice parameter: Management of dementia (an evidence-based review). Report of the quality standards subcommittee of the American academy of neurology. Neurology 2001;56:1154-66.
Trinh NH, Hoblyn J, Mohanty S, Yaffe K. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: A meta-analysis. JAMA 2003;289:210-6.
Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev 2006;2006:CD005593.
Birks JS, Grimley Evans J. Rivastigime for Alzheimer’s disease. Cochrane Database Syst Rev 2015;2015:CD001191.
Birks J, Harvey RJ. Donepezil for dementia due to Alzheimer’s disease. Cochrane Database Syst Rev 2006;2006:CD001190.
Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, et al. Donepezil and memantine for moderate–to–severe Alzheimer’s disease. N Engl J Med 2012;366:893.
Henderson VW. Estrogen, cognition, and a women’s risk of Alzheimer’s disease. Am J Med 1997;103:11S.
Shumaker SA, Legault C, Kuller L, Rapp SR, Thal L, Lane DS, et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women’s health initiative memory study. JAMA 2004;291:2947-58.
Farina N, Llewellyn D, Issac MG, Tabet N. Vitamin E for Alzheimer’s dementia and mild cognitive impairment. Cochrane Database Syst Rev 2017;1:CD002854.
Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer’s disease. The Alzheimer’s disease cooperative study. N Engl J Med 1997;336:1216-22.
Rogers J, Webster S, Lue LF, Brachova L, Civin WH, Emmerling M, et al. Inflammation and Alzheimer’s disease pathogenesis. Neurobiol Aging 1996;17:681-6.
Andersen K, Launer LJ, Ott A, Hoes AW, Breteler MM, Hofman A, et al. Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer’s disease? The Rotterdam study. Neurology 1995;45:1441-5.
Sparks DL, Sabbagh MN, Connor DJ, Lopez J, Launer LJ, Browne P, et al. Atorvastatin for the treatment of mild to moderate Alzheimer disease: Preliminary results. Arch Neurol 2005;62:753-7.
Feldman HH, Doody RS, Kivipelto M, Sparks DL, Waters DD, Jones RW, et al. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology 2010;74:956-64.
Wisniewski T, Boutajangout A. Vaccination as a therapeutic approach to Alzheimer’s disease. Mt Sinai J Med 2010;77:17-31.
Panza F, Frisardi V, Solfrizzi V, Imbimbo BP, Logroscino G, Santamato A, et al. Interacting with γ-secretase for treating Alzheimer’s disease: From inhibition to modulation. Curr Med Chem 2011;18:5430-47.
Eriksen JL, Sagi SA, Smith TE, Weggen S, Das P, McLendon DC, et al. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower abeta 42 in vivo. J Clin Invest 2003;112:440-9.
Selkoe DJ. Clearing the brain’s amyloid cobwebs. Neuron 2001;32:177-80.
Montoliu-Gaya L, Villegas S. Protein structures in Alzheimer’s disease: The basis for rationale therapeutic design. Arch Biochem Biophys 2015;588:1-4.
Aisen PS, Schneider LS, Sano M, Diaz-Arrastia R, van Dyck CH, Weiner MF, et al. High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: A randomized controlled trial. JAMA 2008;300:1774-83.
Regland B, Lehmann W, Abedini I, Blennow K, Jonsson M, Karlsson I, et al. Treatment of Alzheimer’s disease with clioquinol. Dement Geriatr Cogn Disord 2001;12:408-14.
Selkoe DJ. The cell biology of beta-amyloid precursor protein and Presenilin in Alzheimer’s disease. Trends Cell Biol 1998;8:447-53.
Glenner GG, Wong CW. Alzheimer’s disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 1984;120:885-90.
Thal DR, Capetillo-Zarate E, Del Tredici K, Braak H. The development of amyloid beta protein deposits in the aged brain. Sci Aging Knowledge Environ 2006;2006:re1.
Meda L, Baron P, Scarlato G. Glial activation in Alzheimer’s disease: The role of abeta and its associated proteins. Neurobiol Aging 2001;22:885-93.
Kiranjit K, Rajneet K, Manjinder K. Recent advances in Alzheimer’s disease: Cause and treatment. Intl J Pharm Pharm Sci 2016;8:8-15.
Ambili TR, Manimekalan A, Abhijith BD. SiRNA gene therapy for Alzheimer’s disease targeting APP gene. Intl J Pharm Pharm Sci 2012;4:341-6.
Ross CA, Poirier MA. Protein aggregation and neurodegenerative disease. Nat Med 2004;10 Suppl: S10-7.
Jakob-Roetne R, Jacobsen H. Alzheimer’s disease: From pathology to therapeutic approaches. Angew Chem Int Ed Engl 2009;48:3030-59.
Scott LE, Orvig C. Medicinal inorganic chemistry approaches to passivation and removal of aberrant metal ions in disease. Chem Rev 2009;109:4885-910.
Bonda DJ, Lee HG, Blair JA, Zhu X, Perry G, Smith MA. Role of metal dyshomeostasis in Alzheimer’s disease. Metallomics 2011;3:267-70.
Bush AI, Tanzi RE. Therapeutics for Alzheimer’s disease based on the metal hypothesis. Neurotherapeutics 2008;5:421-32.
Rauk A. The chemistry of Alzheimer’s disease. Chem Soc Rev 2009;38:2698-715.
Dobson CM. Protein misfolding and degenerative diseases. Nat Educ 2010;3:28.
Gaggelli E, Kozlowski H, Valensin D, Valensin G. Copper homeostasis and neurodegenerative disorders (Alzheimer’s, prion and Parkinson’s diseases and amyotrophic lateral sclerosis). Chem Rev 2006;106:1995-2044.
Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: Lessons from Alzheimer’s amyloid beta-peptide. Nat Rev Mol Cell Biol 2007;8:101-12.
Lichtenthaler SF, Haass C, Steiner H. Regulated intramembrane proteolysis—lessons from amyloid precursor protein processing. J Neurochem 2011;117:779-96.
Stefani M, Dobson CM. Protein aggregation and aggregate toxicity: New insights into protein folding, misfolding diseases and biological evolution. J Mol Med (Berl) 2003;81:678-99.
Stefani M. Generic cell dysfunction in neurodegenerative disorders: Role of surfaces in early protein misfolding, aggregation, and aggregate cytotoxicity. Neuroscientist 2007;13:519-31.
Davidowitz EJ, Chatterjee I, Moe GS. Targetting tau oligomers for therapeutic development for Alzheimer’s disease and tauopathies. Curr Topics Biotechnol 2008;4:47-64.
Berger Z, Roder H, Hanna A, Carlson A, Rangachari V, Yue M, et al. Accumulation of pathological tau species and memory loss in a conditional model of tauopathy. J Neurosci 2007;27:3650-62.
Irwin DJ, Lee VM, Trojanowski JQ. Parkinson’s disease dementia: Convergence of α-synuclein, tau and amyloid–β pathologies. Nat Rev Neurosci 2013;14:626-36.
Gómez-Ramos A, DÃaz-Hernández M, Cuadros R, Hernández F, Avila J. Extracellular tau is toxic to neuronal cells. FEBS Lett 2006;580:4842-50.
Gómez-Ramos A, DÃaz-Hernández M, Rubio A, Miras-Portugal MT, Avila J. Extracellular tau promotes intracellular calcium increase through M1 and M3 muscarinic receptors in neuronal cells. Mol Cell Neurosci 2008;37:673-81.
Cuanalo-Contreras K, Mukherjee A, Soto C. Role of protein misfolding and proteostasis deficiency in protein misfolding diseases and aging. Int J Cell Biol 2013;2013:638083.
Harper JD, Lansbury PT Jr. Models of amyloid seeding in Alzheimer’s disease and scarpie: Mechanistic truths and physiological consequences of the time–dependent solubility of amyloid proteins. Annu Rev Biochem 1997;66:385-407.
Muoio DM, Newgard CB. Molecular and metabolic mechanisms of insulin resistance and β-cell failure in Type 2 diabetes. Nat Rev Mol Cell Biol 2008;9:193-205.
Kirkman MS, Briscoe VJ, Clark N, Florez H, Haas LB, Halter JB, et al. Diabetes in older adults: A consensus report. J Am Geriatr Soc 2012;60:2342-56.
Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr. Bigger JT, et al. Effects of intensive glucose lowering in Type 2 diabetes. N Engl J Med 2008;358:2545-59.
Höppener JW, Ahrén B, Lips CJ. Islet amyloid and Type 2 diabetes mellitus. N Engl J Med 2000;343:411-9.
Abedini A, Schmidt AM. Mechanisms of islet amyloidosis toxicity in Type 2 diabetes. FEBS Lett 2013;587:1119-27.
Pillay K, Govender P. Amylin uncovered: A review on the polypeptide responsible for Type II diabetes. Biomed Res Int 2013;2013:826706.
Cao P, Tu LH, Abedini A, Levsh O, Akter R, Patsalo V, et al. Sensitivity of amyloid formation by human islet amyloid polypeptide to mutations at residue 20. J Mol Biol 2012;421:282-95.
Hayden MR. Islet amyloid, metabolic syndrome, and the natural progressive history of Type 2 diabetes mellitus. JOP 2002;3:126-38.
De Lorenzi E, Giorgetti S, Grossi S, Merlini G, Caccialanza G, Bellotti V, et al. Pharmaceutical strategies against amyloidosis: Old and new drugs in targeting a protein misfolding diseaseâ€. Curr Med Chem 2004;11:1065-84.
Dandona P, Thusu K, Cook S, Snyder B, Makowski J, Armstrong D, et al. Oxidative damage to DNA in diabetes mellitus. Lancet 1996;347:444-5.
Lemere CA, Oh J, Stanish HA, Peng Y, Pepivani I, Fagan AM, et al. Cerebral amyloid-beta protein accumulation with aging in cotton-top tamarins: A model of early Alzheimer’s disease? Rejuvenation Res 2008;11:321-32.
Janson J, Laedtke T, Parisi JE, O’Brien P, Petersen RC, Butler PC, et al. Increased risk of Type 2 diabetes in Alzheimer disease. Diabetes 2004;53:474-81.
Li W, Prakash R, Kelly-Cobbs AI, Ogbi S, Kozak A, El-Remessy AB, et al. Adaptive cerebral neovascularization in a model of Type 2 diabetes: Relevance to focal cerebral ischemia. Diabetes 2010;59:228-35.
ElAli A, Thériault P, Préfontaine P, Rivest S. Mild chronic cerebral hypoperfusion induces neurovascular dysfunction, triggering peripheral beta-amyloid brain entry and aggregation. Acta Neuropathol Commun 2013;1:75.
Mukherjee E, Carroll R, Matfin G. Endocrine and metabolic emergencies: Hypoglycaemia. Ther Adv Endocrinol Metab 2011;2:81-93.
Hachinski V, Iadecola C, Petrsen RC, Breteler MM, Nyenhuis DL, Black SE, et al. National institute of neurological disorders and stroke-Canadian stroke network vascular cognitive imapirment harmonization standards. Stroke 2006;37:2220-41.
Abramov E, Dolev I, Fogel H, Ciccotosto GD, Ruff E, Slutsky I, et al. Amyloid-beta as a positive endogenous regulator of release probability at hippocampal synapses. Nat Neurosci 2009;12:1567-76.
Morley JE, Farr SA. The role of amyloid-beta in the regulation of memory. Biochem Pharmacol 2014;88:479-85.
Lam AR, Rodriguez JJ, Rojas A, Scheraga HA, Mukamel S. Tracking the mechanism of fibril assembly by simulated two-dimensional ultraviolet spectroscopy. J Phys Chem A 2013;117:342-50.
De Felice FG, Ferreira ST. Inflammation, defective insulin signalling, and mitochondrial dysfunction as common molecular denominators connecting Type 2 diabetes to Alzheimer disease. Diabetes 2014;63:2262-72.
Talbot K, Wang HY, Kazi H, Han LY, Bakshi KP, Stucky A, et al. Demonstrated brain insulin resistance in Alzheimer’s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest 2012;122:1316-38.
Talbot K, Wang HY. The nature, significance, and glucagon-like peptide-1 analog treatment of brain insulin resistance in Alzheimer’s disease. Alzheimers Dement 2014;10:S12-25.
Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999;400:173-7.
Strittmatter WJ, Weisgraber KH, Huang DY, Dong LM, Salvesen GS, Pericak-Vance M, et al. Binding of human apolipoprotein E to synthetic amyloid beta peptide: Isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci U S A 1993;90:8098-102.
Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PH, Pericak-Vance MA, Joo SH, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer’s disease. Neurology 1993;43:1467-72.
Martin ER, Scott WK, Nance MA, Watts RL, Hubble JP, Koller WC, et al. Association of single-nucleotide polymorphisms of the tau gene with late-onset Parkinson disease. JAMA 2001;286:2245-50.
Cole N, Siddique T. Genetic disorders of motor neurons. Semin Neurol 1999;19:407-18.
Giasson BI, Forma MS, Higuchi M, Golbe LI, Graves CL, Kotzbauer PT, Trojanowski JQ, and Lee VM. Sciences2 003; 300(5619): 636 – 40.
Gatz M, Reynolds CA, Fratiglioni L, Johansson B, Mortimer JA, Berg S, et al. Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry 2006;63:168-74.
Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh compound-B. Ann Neurol 2004;55:306-19.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
